Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:physicians:concerns [02.09.2019] – [Concerns about lack of clinical evidence] sallieqhome:physicians:concerns [02.09.2019] – [Concerns about lack of clinical evidence] sallieq
Line 17: Line 17:
   * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}}))   * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}}))
   * patients' expressed preferences and values(({{pubmed>long:19050187}}))   * patients' expressed preferences and values(({{pubmed>long:19050187}}))
-  * additional material on patient response, see below update+  * more recent material on patient response, see below update
   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]
   * orphan drug status – Autoimmunity Research Foundation has won [[home:publications:applications_orphan_status|orphan drug status]] from the FDA for several medications and indications, and is committed to working further with the agency to get the MP approved for a broader range of indications.   * orphan drug status – Autoimmunity Research Foundation has won [[home:publications:applications_orphan_status|orphan drug status]] from the FDA for several medications and indications, and is committed to working further with the agency to get the MP approved for a broader range of indications.
home/physicians/concerns.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.